We recently published a list of Thursday’s 10 Worst-Performing Stocks. In this article, we are going to take a look at where Alumis Inc. (NASDAQ:ALMS) stands against other Thursday’s worst-performing ...
The average one-year price target for Alumis (NasdaqGS:ALMS) has been revised to $40.35 / share. This is an increase of 11.20% from the prior estimate of $36.28 dated February 21, 2026. The price ...
Drug maker Alumis (ALMS) is climbing 7% after investment bank Oppenheimer started coverage of the name with an Outperform rating. Why Oppenheimer Is Bullish on ALMS Due to concerns about Alumis' cash ...
Alumis Inc. (NASDAQ:ALMS) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 21, Alumis Inc. (NASDAQ:ALMS) reported that it has completed its merger with ACELYRIN, Inc. As part of this ...
Alumis announced strong phase three trial results for its plaque psoriasis drug Biotech stock Alumis Inc (NASDAQ:ALMS) is skyrocketing today, up 107.9% at $17.28 at last glance, after the Johnson & ...
Learn more about Alumis Inc.'s (ALMS) stock grades for Value, Momentum and Estimate Revisions and determine whether this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results